Impact of Emerging Therapies on Outcomes for EGFR-Mutated NSCLC
Alan Chin, PharmD, BCOP, examines the PALOMA-3 trial's influence on the treatment of EGFR-mutated metastatic NSCLC and explores the evolving role of antibody-drug conjugates (ADCs) in the therapeutic landscape of EGFR-mutated NSCLC.
- How might the advent of subcutaneous amivantamab, currently being studied in the PALOMA-3 trial, impact the treatment of EGFR-mutated metastatic NSCLC? What opportunities or challenges might this impose?
- How do you see the role of antibody-drug conjugates (ADCs) evolving in the treatment landscape of EGFR-mutated NSCLC, and are there any in the pipeline that you are particularly excited about?